KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Long-Term Deferred Tax: 2009-2019

  • Novavax's Long-Term Deferred Tax fell 20.96% to $2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was $2.5 million, marking a year-over-year decrease of 20.96%. This contributed to the annual value of $2.5 million for FY2019, which is 20.96% down from last year.
  • Per Novavax's latest filing, its Long-Term Deferred Tax stood at $2.5 million for Q4 2019, which was down 20.96% from $3.2 million recorded in Q4 2018.
  • Novavax's Long-Term Deferred Tax's 5-year high stood at $3.2 million during Q4 2018, with a 5-year trough of $2.5 million in Q4 2019.
  • Its 2-year average for Long-Term Deferred Tax is $2.8 million, with a median of $2.8 million in 2018.
  • Data for Novavax's Long-Term Deferred Tax shows a maximum YoY dropped of 20.96% (in 2019) over the last 5 years.
  • Quarterly analysis of 2 years shows Novavax's Long-Term Deferred Tax stood at $3.2 million in 2018, then declined by 20.96% to $2.5 million in 2019.
  • Its Long-Term Deferred Tax was $2.5 million in Q4 2019, compared to $3.2 million in Q4 2018 and $108.2 million in Q4 2010.